Ibrance

Active Ingredient(s): Palbociclib
FDA Approved: * February 3, 2015
Pharm Company: * PFIZER INC
Category: Cancer

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.[1][2] Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.[3] Contents 1 Mechanism of action 2 Administration 3 Approvals and indications 3.1 HR+ breast cancer 4 Adverse effects 5 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ibrance 75 mg Oral Capsule
NDC: 0069-0187
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 100 mg Oral Capsule
NDC: 0069-0188
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 125 mg Oral Capsule
NDC: 0069-0189
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 75 mg Oral Tablet, Film Coated
NDC: 0069-0284
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 100 mg Oral Tablet, Film Coated
NDC: 0069-0486
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 125 mg Oral Tablet, Film Coated
NDC: 0069-0688
Labeler:
Pfizer Laboratories Div Pfizer Inc
Ibrance 75 mg Oral Capsule
NDC: 63539-187
Labeler:
U.S. Pharmaceuticals
Ibrance 100 mg Oral Capsule
NDC: 63539-188
Labeler:
U.S. Pharmaceuticals
Ibrance 125 mg Oral Capsule
NDC: 63539-189
Labeler:
U.S. Pharmaceuticals
Ibrance 75 mg Oral Tablet, Film Coated
NDC: 63539-284
Labeler:
Us Pharmaceuticals
More Results